Dr. Reddy's Laboratories Limited (BOM: 500124)
India
· Delayed Price · Currency is INR | Market Cap | 1.02T |
| Revenue (ttm) | 299.87B |
| Net Income (ttm) | 53.33B |
| Shares Out | 832.96M |
| EPS (ttm) | 63.95 |
| PE Ratio | 19.17 |
| Forward PE | 16.59 |
| Dividend | 8.00 (0.65%) |
| Ex-Dividend Date | Jul 16, 2024 |
| Volume | 35,384 |
| Open | 1,254.55 |
| Previous Close | 1,245.70 |
| Day's Range | 1,222.25 - 1,254.55 |
| 52-Week Range | 1,074.35 - 1,420.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2024 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Financial Performance
In 2023, Dr. Reddy's Laboratories's revenue was 279.16 billion, an increase of 13.54% compared to the previous year's 245.88 billion. Earnings were 55.68 billion, an increase of 23.56%.
Financial StatementsNews
Dr Reddy's Laboratories CEO on becoming a market leader in India
Erez Israeli, CEO of Dr Reddy's Laboratories highlights the moves he is undertaking to position his company as a market leader in India. He discusses the acquisition of a nicotine replacement therapy ...
Dr. Reddy's reports Q2 results
Dr. Reddy’s Laboratories shares jump 2% as company clocks highest-ever revenue in Q2
Dr. Reddy’s Laboratories (DRL) saw its shares jump more than 2% after reporting a significant 16.5% increase in revenue for Q2 FY25, reaching a record-high Rs 8,016.1 crore. Despite a 9.5% year-on-yea...
BofA expects 20% upside in Dr Reddy’s, maintains buy with target of Rs 1,530
Bank of America (BofA) has reiterated its buy rating on Dr Reddy’s Laboratories, setting a target price of ₹1,530, suggesting a 20% upside from the current market price of ₹1,276.90. The brokerage hig...
Jefferies maintains underperform on Dr Reddy’s, sees 11% downside from current share price
Jefferies has reiterated its underperform rating on Dr Reddy’s Laboratories, setting a target price of ₹1,130, implying a potential downside of 11% from the current market price of ₹1,276.90. The comp...
DRL Q2 net falls 15% despite revenue surge
HYDERABAD: Pharma major Dr Reddy's Laboratories on Tuesday reported a 15% drop in consolidated net profit for the Sept quarter, despite its quarterly .
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ETCompany ParticipantsRicha Periwal - Head of Investor...
Dr. Reddy's Laboratories Limited 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2025 Q2 earnings call.
Dr. Reddy's Q2 & H1FY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024.
Dr. Reddy’s Labs Q2 FY25 Results: Revenue grows 16.5% YoY to 8016 crore, Net Profit down 15.3%
Dr. Reddy’s Laboratories has released its consolidated financial results for the second quarter of fiscal year 2025 (Q2 FY25), reporting notable growth in revenue. The company’s board also approved a ...
Key stocks to watch as Dr Reddy’s, Titan, GAIL, Mankind Pharma, Berger Paints, Waaree Renewables prepare for Q2 FY24-25 results today
Investors are set to focus on several key companies scheduled to announce their Q2 FY24-25 results today. The stock prices as of yesterday’s close indicate mixed sentiment across sectors, and today’s ...
Dr. Reddy's Q2 2025 Earnings Preview
Dr. Reddy’s Laboratories launches Elobixibat (BixiBat®) to treat chronic constipation in India
Dr. Reddy’s Laboratories Ltd has announced the launch of BixiBat®, a first-in-class drug for treating chronic constipation in India. This innovative medication, known scientifically as Elobixibat, has...
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanAssociationfortheAdvancementofScience--Dr. Reddy's has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Su...
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehe...
Stocks to Watch on October 17 2024: L&T Tech, Bajaj Auto, CRISIL, RailTel, Bikaji, Reliance and more
At market close on October 16, 2024, the Sensex was down 318.76 points or 0.39%, closing at 81,501.36, while the Nifty fell 86 points or 0.34%, closing at 24,971.30. On the Nifty, top losers included ...
Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today
JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.
Revlimid lawsuit in US: Dr Reddy’s added as defendant by three groups
Dr Reddy's Laboratories faces new claims as three groups of plaintiffs join an ongoing antitrust lawsuit related to Revlimid in the US, igniting a legal battle with major healthcare insurers and trust...
Dr Reddy's, arm named defendant by more plaintiffs in Revlimid anti-trust lawsuit in US
Dr Reddy's Laboratories and its subsidiary are named as defendants in a growing number of lawsuits related to the Revlimid antitrust case in the US, as healthcare companies and trusts seek justice. Th...
Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's launches comprehensive menopause support program and training for employees during menopause awareness month.
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector
Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delv...
Dr Reddy’s co gets nod for cell therapy phase-2 trials
Dr Reddy's Laboratories' subsidiary, Aurigene Oncology, has been authorized by the DCGI to initiate phase-2 trials for Ribrecabtagene autoleucel, a novel CAR-T cell therapy targeting multiple myeloma,...
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy...
Aurigene Oncology gets DCGI nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucel
Dr Reddy’s Laboratories' subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India's first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene au...
Dr. Reddy’s Laboratories subsidiary announces promising Phase 1 results for autologous CAR-T cell therapy
Aurigene Oncology, a Dr. Reddy’s subsidiary, recently announced promising Phase 1 results for Ribrecabtagene autoleucel (DRL-1801), India’s first novel autologous CAR-T cell therapy for multiple myelo...